Skip to main content Skip to navigation
Make an Appointment Today 1-888-884-BEAR (2327) 1-888-884-BEAR (2327)
Find a Doctor Donate
Call Us Menu
We care about your privacy. Read about your rights and how we protect your data. Get Details
In this section More on this Topic

Coronavirus Update: What patients and families need to know

Innovations in drug development: How Children's National is taking a leadership role in faster, better and cheaper drugs

Share:
Linked In Print Email

A. James Clark Distinguished Professorship in Molecular Genetics
Innovations in Drug Development: How Children’s National is Taking a Leadership Role in Faster, Better and Cheaper Drugs 

Presented by: 

Eric Hoffman, Ph.D.
Director, Research Center for Genetic Medicine, Children’s National
Professor and Chairman, Department of Integrative Systems Biology, George Washington University
Co-Founder, ReveraGen Biopharma

Give Act

Invest in future cures for some of life's most devastating diseases

See other ways to give

Share your birthday with a child. Celebrate your life, and give a chance to someone who desperately wants to have as many as you.

Share your birthday with a child. Celebrate your life, and give a chance to someone who desperately wants to have as many as you. Make it happen

You Might Also Be Interested In:

Muscular Dystrophies

Muscular dystrophy describes a genetic disorder of the muscles that causes the muscles in the body to become very weak. 

Genetics Expert Talks about Tensions Between Parents and Regulators over Duchenne Treatments

In a feature story in Bloomberg Businessweek about Duchenne muscular dystrophy, Eric Hoffman, PhD, discusses the current tension that exists between families and drug regulators.

Rare Diseases Expert Talks about Research in Duchenne Treatments

Eric Hoffman, PhD, discusses the progress in discovering novel treatments for Duchenne muscular dystrophy with the Washington Post.

International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug

A novel anti-inflammatory in development for the chronic treatment of Duchenne muscular dystrophy by ReveraGen BioPharma,  a private spin-off company from Children’s National Health System, has received $2 million from four nonprofit organizations.